Kisspeptin vs PT-141: Different Paths to Desire

Key takeaways

• These are different molecules on different paths. PT-141 (bremelanotide) acts on melanocortin receptors in desire pathways and is FDA-approved for premenopausal women with low desire. Kisspeptin acts at the top of the reproductive hormone axis and is approved nowhere.
• PT-141 has two 24-week phase 3 trials in 1,247 women and a small, real effect: desire up about 0.35 points on a 1.2-to-6 scale, no increase in satisfying sexual events, nausea in 40%.
• Kisspeptin has two single-infusion trials, 32 men and 32 women, whose primary outcome was brain activity on MRI. Men also showed more tumescence and more happiness about sex; women's desire scores did not move.
• Nobody has compared them, nobody has combined them, and kisspeptin has never been tested as a repeated self-administered dose for desire.
• Only one of the two can be prescribed in the United States today. Kisspeptin-10 is in FDA's Category 2 and its advisory committee voted 0 to 11 against it in 2024.

If you are choosing between them, the choice is not close, and not because kisspeptin is bad science. PT-141 is an approved drug with a label, a known dose, a measured effect that is statistically solid and clinically small, and a legal path through a pharmacy. Kisspeptin is an investigational hormone whose entire libido evidence is two laboratory trials in which 64 people received one intravenous infusion each while their brains were scanned, and which no US pharmacy may legally prepare. One is a modest treatment option a clinician can discuss; the other is a research compound sold illegally as if it were a product. The kisspeptin-10 profile covers kisspeptin in full, kisspeptin dosage sets out what the studies actually administered, and the PT-141 profile does the same for bremelanotide.

Side by side

Sources: kisspeptin rows from Thurston 2022, Mills 2023, Yeung 2026, FDA's Category 2 list and the October 2024 committee minutes; PT-141 rows from the Vyleesi label, Kingsberg 2019 and Spielmans 2021, with the detail in the PT-141 hub.

Different problems, different targets

The two compounds answer different questions about why desire is low.

PT-141 goes straight at desire. Bremelanotide came out of the observation that a melanocortin agonist being tested as a tanning agent caused erections, and it was developed as an as-needed drug for sexual motivation. It does not change testosterone or estrogen; the label is candid that the mechanism of its effect in HSDD is unknown. Its half-life is short, which is why it is taken before sex rather than daily. In men, subcutaneous doses of 4 and 6 mg produced measurable erections in laboratory studies of sildenafil non-responders in 2004 (Rosen 2004), and intranasal doses above 7 mg did the same with onset at about 30 minutes (Diamond 2004), but the development program for men stalled over blood pressure and nothing was ever approved for them.

Kisspeptin goes at the hormone axis, and brushes desire on the way. Its documented job is switching on GnRH release. The sexual-processing work began when the Imperial College group noticed that kisspeptin receptors also sit in limbic brain regions, and showed in 29 healthy young men that an infusion enhanced limbic activity in response to sexual and couple-bonding images, with reduced negative mood (Comninos 2017). The infusion was deliberately timed so that testosterone had no chance to rise, so this is a brain effect rather than a hormone effect. That is a scientifically important finding and, so far, a finding about brain activity during an infusion.

One practical difference follows. If low desire comes with low testosterone and a desire for fertility, kisspeptin's mechanism is at least aimed at the right system, while PT-141 is not; but the approved tools for that problem are hCG and testosterone, and kisspeptin's hormone effects fade with repeated dosing (Yeung 2026). If the hormones are normal and desire itself is the problem, PT-141 is the one of the two with trial evidence in that population.

Who each is for, according to the evidence

A premenopausal woman with distressing low desire is the only group with randomized evidence for either compound at a usable dose, and that evidence belongs to PT-141. The honest summary is a small effect: about a third of a point on a 1.2-to-6 desire scale, a similar fall in distress, no change in how often sex is satisfying, nausea in four women out of ten and an 18% dropout rate for side effects; an independent re-analysis of the FDA application concluded that participants substantially preferred placebo (Spielmans 2021). The PT-141 for women guide covers the decision in detail. Kisspeptin's trial in this exact population changed brain responses and did not change desire scores (Thurston 2022).

A man with low desire has nothing approved and two weak options. Kisspeptin produced the more interesting signal: in 32 men with HSDD, one infusion modulated the sexual-processing network, increased tumescence during a sexual video by up to 56% over placebo, and raised reported happiness about sex (Mills 2023). That is the best case anyone has made for a peptide for male low desire, and it is one dose, given intravenously, in a scanner, with no legal way to repeat it. PT-141 for men is off-label, resting on laboratory erection data from 2004 at doses two to three times the female label dose, where the blood-pressure problem lives.

A postmenopausal woman has evidence for neither. PT-141's label states it is not indicated after menopause, and kisspeptin's trial enrolled premenopausal women only; after menopause LH and FSH are already high and the ovaries no longer respond, so kisspeptin has no plausible route to helping. Transdermal testosterone is the option with randomized evidence.

Anyone whose low desire has a cause is in the group both compounds will disappoint. The HSDD definition excludes low desire explained by a medication, most often an antidepressant, by a medical or psychiatric condition, or by the relationship. Neither peptide treats any of those.

What a clinician can actually prescribe today

For low desire, the prescribable option is bremelanotide, with its limits stated plainly:

• The approved population is narrow. Premenopausal women with acquired, generalized HSDD. Everything else, including every use in men, is off label.
• The dose and the ceiling are on the label. 1.75 mg under the skin, at least 45 minutes before anticipated sex, no more than one dose in 24 hours and no more than eight a month, with daily dosing the pattern that darkened skin in 38% of women within eight days in a separate study.
• There is a stop rule. The label tells prescribers to discontinue after eight weeks without improvement. A clinic that keeps refilling without asking is not following it.
• Blood pressure gates it. Every dose raises systolic pressure for a few hours; it is contraindicated in uncontrolled hypertension and known cardiovascular disease and not recommended at high cardiovascular risk.
• Pregnancy is a hard stop, with contraception required and discontinuation if pregnancy is suspected.
• Compounded versions are legal within a limit. Bremelanotide is the active ingredient of an approved drug, so a 503A pharmacy may compound it on a prescription, subject to the federal rule against routinely copying a commercially available product; compounded injections at other strengths and nasal sprays are the usual forms, and the sprays have no efficacy data at the doses dispensed. The legal tracker has the framework.

For kisspeptin there is nothing to prescribe. FDA's advisory committee reviewed kisspeptin-10 on October 29, 2024, for the treatment of secondary hypogonadism in men, the use its nominator had proposed, and voted 0 yes, 11 no, 0 abstentions, unanimously agreeing it should not go on the permitted list for lack of convincing safety and efficacy data (FDA PCAC minutes 2024). Nobody nominated it for low desire at all. It remained on FDA's Category 2 list when we checked in October 2026 (FDA Category 2 list). A clinic offering kisspeptin for libido is offering a research vial, and a clinic offering both as a stack is adding an untested combination to an unapproved drug.

Bottom line

Kisspeptin versus PT-141 is a comparison between a research program and a product. PT-141 wins on everything that can be checked: an approval, a label, a dose, two large trials, a known side-effect profile and a legal pharmacy. What it offers in return is a small effect at the cost of frequent nausea, which is why its label builds in an eight-week decision point.

Kisspeptin is the more interesting science and, for men with low desire, has produced the more striking single-dose result. It is also the one you cannot legally obtain, cannot dose in any studied way outside a research unit, and whose hormone effects weaken when given repeatedly. If kisspeptin becomes a treatment for low desire, it will be through trials of a repeated or nasal formulation that have not been run yet.

Frequently asked questions

+−Is kisspeptin the same as PT-141?

No. They are different molecules acting on different receptors. PT-141 (bremelanotide) is a melanocortin-receptor agonist, a relative of the hormone that darkens skin, and it is FDA-approved as Vyleesi for premenopausal women with low sexual desire. Kisspeptin is the hormone at the top of the reproductive axis, which drives LH, FSH and then testosterone or estrogen; no kisspeptin product is approved anywhere, and it has been studied for desire only as an intravenous infusion in a laboratory.

+−Which works better for libido, kisspeptin or PT-141?

Nobody has compared them, and the two evidence bases are not equivalent. PT-141 has two 24-week phase 3 trials in 1,247 premenopausal women, with a small effect: desire rose about 0.35 points more than placebo on a 1.2-to-6 scale and satisfying sexual events did not increase. Kisspeptin has two single-infusion trials of 32 men and 32 women whose main outcome was brain activity on MRI. One is a marketed drug with a modest effect; the other is a research compound.

+−Can a doctor prescribe kisspeptin for low desire?

No. Bremelanotide is an approved drug, so a licensed clinician can prescribe it, including off label, and a pharmacy can compound it within limits. Kisspeptin-10 has been on FDA's Category 2 list since September 2023 and FDA's compounding advisory committee voted 0 to 11 against allowing pharmacies to use it in October 2024, so there is no legal supply. A prescription cannot make a non-compoundable substance compoundable.

+−Is kisspeptin better for women or for men?

On the published evidence, kisspeptin's measurable effects were larger in men. In the trial in 32 men with low desire, brain responses changed, penile tumescence rose, and self-reported happiness about sex improved. In the trial in 32 premenopausal women, brain responses changed but desire and arousal scores did not. PT-141 runs the other way: it is approved for premenopausal women and was never approved for men, whose data stop at laboratory studies from 2004.

+−Can you stack kisspeptin and PT-141?

No study has given the two together, so there is no evidence about either benefit or risk, and no legal kisspeptin product to combine with anything. The combination is also a mismatch of logic: PT-141 is an as-needed drug taken before sex with a short duration, while kisspeptin's reproductive effects fade when it is given repeatedly. Anyone selling a stack is selling an untested combination that includes an unapproved drug.

+−What is the most effective peptide for increasing female arousal?

Bremelanotide is the only peptide with an FDA approval for a sexual indication in women, so by default it is the most proven, and its effect is small and on desire rather than arousal. Kisspeptin changed brain responses to erotic videos in women with low desire but did not change their desire or arousal scores. For arousal, dryness or pain after menopause, low-dose vaginal estrogen has far more evidence than any peptide.

+−Does kisspeptin raise testosterone the way PT-141 does not?

Kisspeptin does act on the hormonal axis: single intravenous doses and short infusions raised LH, FSH and testosterone in small groups of men, which PT-141 does not do at all. But that is not the same as a treatment. Repeated or continuous kisspeptin exposure blunted the hormone response within days, and a long-acting kisspeptin analog lowered testosterone into the castration range, which is what it was being developed for.

+−Which is safer?

Their known risks differ in kind. PT-141 has a full label: nausea in 40% of women, 18% stopping for side effects, a transient blood-pressure rise after every dose, patchy skin darkening, and contraindications in uncontrolled hypertension and known cardiovascular disease. Kisspeptin reported no adverse effects in its small, short trials, but its risks are mostly unmeasured, and FDA flagged possible immune reactions to injected preparations plus an animal study in which it accelerated atherosclerosis.

Sources

1. LabelCosette Pharmaceuticals. VYLEESI (bremelanotide injection) prescribing information, revised March 2024. DailyMed. (2024)
2. StudyKingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899-908. (2019)
3. ReviewSpielmans GI. Re-analyzing phase III bremelanotide trials for 'hypoactive sexual desire disorder' in women. J Sex Res 2021;58:1085-105. (2021)
4. StudyRosen RC et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004;16:135-42. (2004)
5. StudyDiamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004;16:51-9. (2004)
6. StudyThurston L et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open 2022;5:e2236131. (2022)
7. StudyMills EG et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open 2023;6:e2254313. (2023)
8. StudyComninos AN et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest 2017;127:709-19. (2017)
9. StudyYeung AC et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol 2026;195:206-16. (2026)
10. RegulatoryFDA. Final summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 (kisspeptin-10: 0 yes, 11 no, 0 abstain). (2024)
11. RegulatoryFDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list; kisspeptin-10 added September 29, 2023).